Shun Hu
Research Subjects
Shun Hu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chengzhou Zhu
State Key Laboratory of Green Pesticide International Joint Research Center for Intelligent Biosensing Technology and Health College of Chemistry Central China Normal University Wuhan P.R. China
1 shared publication - Haiming Luo
Huazhong University of Science and Technology
1 shared publication Hengjia Wang
State Key Laboratory of Green Pesticide, International Joint Research Center for Intelligent Biosensing Technology and Health, College of Chemistry
1 shared publicationJiaying Bei
National “111” Center for Cellular Regulation and Molecular Pharmaceutics, Key Laboratory of Fermentation Engineering (Ministry of Education), Cooperative Innovation Center of Industrial Fermentation (Ministry of Education & Hubei Province), School of Life and Health Sciences
1 shared publication- Jie Yang
MOE Key Laboratory for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics
1 shared publication - Liding Zhang
Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics, Huazhong University of Science and Technology, Wuhan, China
1 shared publication
Latest Publications
- 21 April 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (17) , 12833-12841
Single-Atom Fe/Au Nanozymic Electrode to Accelerate Glucose Oxidation for Self-Powered Sensing
Self-powered sensing based on enzymatic biofuel cells (EBFCs) provides a promising platform for miniaturized and portable exosome analysis by converting biochemical reactions directly into electrical output. However, the operational reliability of such systems remains fundamentally restricted by the instability, limited electron-transfer efficiency, and high cost of natural enzymes. Herein, we design a heteroatomic nanozyme featuring Fe single atoms electronically coupled to Au nanoparticles anchored on nitrogen-doped carbon (FeSA-AuNP/NC) to enhance glucose oxidation. When paired with a FeSA/NC cathode, FeSA-AuNP/NC serves as an efficient nanozymatic anode to construct a fully nanozyme-driven BFC. The fully nanozymic BFC displays markedly higher electrical output and improved operational durability relative to the BFC using a GOx-based bioanode. As a proof of concept, this fully nanozymatic system enables quantitative and sensitive exosome detection across a wide linear range (103-107 particles mL-1) with an ultralow detection limit of 362 particles mL-1, highlighting the promise of electronically regulated interfaces to advance next-generation self-powered biosensing platforms.
- 21 April 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (17) , 12833-12841
Single-Atom Fe/Au Nanozymic Electrode to Accelerate Glucose Oxidation for Self-Powered Sensing
Self-powered sensing based on enzymatic biofuel cells (EBFCs) provides a promising platform for miniaturized and portable exosome analysis by converting biochemical reactions directly into electrical output. However, the operational reliability of such systems remains fundamentally restricted by the instability, limited electron-transfer efficiency, and high cost of natural enzymes. Herein, we design a heteroatomic nanozyme featuring Fe single atoms electronically coupled to Au nanoparticles anchored on nitrogen-doped carbon (FeSA-AuNP/NC) to enhance glucose oxidation. When paired with a FeSA/NC cathode, FeSA-AuNP/NC serves as an efficient nanozymatic anode to construct a fully nanozyme-driven BFC. The fully nanozymic BFC displays markedly higher electrical output and improved operational durability relative to the BFC using a GOx-based bioanode. As a proof of concept, this fully nanozymatic system enables quantitative and sensitive exosome detection across a wide linear range (103-107 particles mL-1) with an ultralow detection limit of 362 particles mL-1, highlighting the promise of electronically regulated interfaces to advance next-generation self-powered biosensing platforms.
- Top Cited PapersOpen Access
- 29 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (13) , eabm3088
Sensitive detection of multiple blood biomarkers via immunomagnetic exosomal PCR for the diagnosis of Alzheimer’s disease
Blood exosomes are emerging as potential biomarkers for diagnosing brain diseases such as Alzheimer’s disease (AD). There is currently a lack of an ultrasensitive technology for identifying core AD biomarkers in blood exosomes to optimize the utility of biomarkers in clinical practice. Here, an immunomagnetic exosomal polymerase chain reaction (iMEP) platform was developed using DNA-conjugated antibodies for the rapid detection of amyloid-β (Aβ 1–40 and Aβ 1–42 ) and phosphorylated tau (p-tau 396,404 and p-tau 181 ) in clinical blood exosomes. The toehold shift–mediated DNA affinity pulldown eliminates the high detection background, which allows the detection of biomarkers at concentrations down to 10 femtograms per milliliter. With the iMEP assay, exosomal Aβ 1–42 was more accurate in differentiating patients with AD from healthy individuals compared with exosomal p-tau 181 and p-tau 396,404 , with a sensitivity of 95.0% and a specificity of 95.0%. The iMEP technique is also adept at quantifying the levels of different exosomal biomarkers associated with disease pathogenesis.
- 29 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (13) , eabm3088
Top Cited PapersOpen AccessSensitive detection of multiple blood biomarkers via immunomagnetic exosomal PCR for the diagnosis of Alzheimer’s disease
Blood exosomes are emerging as potential biomarkers for diagnosing brain diseases such as Alzheimer’s disease (AD). There is currently a lack of an ultrasensitive technology for identifying core AD biomarkers in blood exosomes to optimize the utility of biomarkers in clinical practice. Here, an immunomagnetic exosomal polymerase chain reaction (iMEP) platform was developed using DNA-conjugated antibodies for the rapid detection of amyloid-β (Aβ 1–40 and Aβ 1–42 ) and phosphorylated tau (p-tau 396,404 and p-tau 181 ) in clinical blood exosomes. The toehold shift–mediated DNA affinity pulldown eliminates the high detection background, which allows the detection of biomarkers at concentrations down to 10 femtograms per milliliter. With the iMEP assay, exosomal Aβ 1–42 was more accurate in differentiating patients with AD from healthy individuals compared with exosomal p-tau 181 and p-tau 396,404 , with a sensitivity of 95.0% and a specificity of 95.0%. The iMEP technique is also adept at quantifying the levels of different exosomal biomarkers associated with disease pathogenesis.